Select a Sector or Industry
Long Term Debt Rankings for Drug Manufacturers - Major Industry
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
| Rank | Symbol | Company |
Long Term Debt
|
Pro Rating
|
|---|---|---|---|---|
| 1 | ACRX | AcelRx Pharmaceuticals | 0.00 | Go Pro |
| 1 | CPHI | China Pharma | 0.00 | Go Pro |
| 1 | SNY | Sanofi | 0.00 | Go Pro |
| 1 | SKBI | Skystar Bio - Pharmaceutical Company | 0.00 | Go Pro |
| 1 | ASTX | Astex Pharmaceuticals | 0.00 | Go Pro |
| 1 | RIGL | Rigel Pharmaceuticals | 0.00 | Go Pro |
| 1 | IPXL | Impax Laboratories | 0.00 | Go Pro |
| 1 | WX | WuXi PharmaTech | 0.00 | Go Pro |
| 1 | VTUS | Ventrus Biosciences | 0.00 | Go Pro |
| 1 | KERX | Keryx Biopharmaceuticals | 0.00 | Go Pro |
| 11 | ALIM | Alimera Sciences | 2.332M | Go Pro |
| 12 | AXN | Aoxing Pharmaceutical Company | 8.803M | Go Pro |
| 13 | AEGR | Aegerion Pharmaceuticals | 10.00M | Go Pro |
| 14 | ECYT | Endocyte | 12.84M | Go Pro |
| 15 | ANTH | Anthera Pharmaceuticals | 17.34M | Go Pro |
| 16 | KUN | China Shenghuo Pharmaceutical | 22.11M | Go Pro |
| 17 | PCRX | Pacira Pharmaceuticals | 25.00M | Go Pro |
| 18 | ZGNX | Zogenix | 55.40M | Go Pro |
| 19 | LLY | Eli Lilly and Company | 5.414B | Go Pro |
| 20 | BMY | Bristol-Myers Squibb Company | 5.415B | Go Pro |
| 21 | AZN | AstraZeneca Group | 9.383B | Go Pro |
| 22 | JNJ | Johnson & Johnson | 13.01B | Go Pro |
| 23 | MRK | Merck | 15.23B | Go Pro |
| 24 | ABT | Abbott Laboratories | 16.65B | Go Pro |
| 25 | GSK | GlaxoSmithKline | 18.84B | Go Pro |
| 26 | NVS | Novartis | 24.59B | Go Pro |
| 27 | PFE | Pfizer | 33.54B | Go Pro |
